Epidemiology of inhibitors in haemophilia A

被引：40

作者：

Kreuz, W

EscuriolaEttingshausen, C

MartinezSaguer, I

Gungor, T

Kornhuber, B

机构：

来源：

VOX SANGUINIS | 1996年 / 70卷

关键词：

FACTOR-IX INHIBITORS; FACTOR-VIII; HEMOPHILIA-A; VIRAL SAFETY; PREVALENCE;

D O I：

10.1111/j.1423-0410.1996.tb01341.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

One of the most serious complications of the treatment of haemophilia A is the development of inhibitors. Former studies mostly considered the prevalence of inhibitor development, thus underestimating its true risk. Prevalences ranged widely (7-18%) probably due to the populations studied and the study design. Recent prospective previously untreated patients (PUP) studies were more comparable because of similar study designs. Eight PUP studies regarding the incidence of factor WI inhibitors were analyzed: The inhibitor incidences (Independent of severity of haemophilia) ranged from 18.4 to 28%. Evaluating only severe haemophiliacs (factor VIII < 2%) significantly higher incidences were found. After 9-36 exposure days (as medians inhibitor development occurred at 0.8-3.3 years of age (as medians).

引用

页码：2 / 8

页数：7

共 20 条

[1] FREQUENCY OF INHIBITOR DEVELOPMENT IN HEMOPHILIACS TREATED WITH LOW-PURITY FACTOR-VIII [J].

ADDIEGO, J ;

KASPER, C ;

ABILDGAARD, C ;

HILGARTNER, M ;

LUSHER, J ;

GLADER, B ;

ALEDORT, L .

LANCET, 1993, 342 (8869) :462-464

[2]

ALEDORT L, 1992, 9 INT SOC THROMB HAE

[3]

[Anonymous], BLOOD S1

[4]

BRAY G, 1994, 21 INT C WORLD FED H

[5]

BRAY GL, 1992, BLOOD S, V80, P229

[6]

BRAY GL, 1992, 20 INT C WORLD FED H, P83

[7]

DEBIASI R, 1994, THROMB HAEMOSTASIS, V71, P544

[8] INCIDENCE OF DEVELOPMENT OF FACTOR-VIII AND FACTOR-IX INHIBITORS IN HEMOPHILIACS [J].

EHRENFORTH, S ;

KREUZ, W ;

SCHARRER, I ;

LINDE, R ;

FUNK, M ;

GUNGOR, T ;

KRACKHARDT, B ;

KORNHUBER, B .

LANCET, 1992, 339 (8793) :594-598

[9]

Gill F M, 1984, Prog Clin Biol Res, V150, P19

[10]

KREUZ W, 1994, ERSTES DTSCH KOGENAT, P126

← 1 2 →